IL17A and neoplasm: In contrast, Th17-derived IL-17 is also shown to promote anti-tumor immunity by enhancing IFN-γ+ NK- and effector T cell activation (169) and CCL20-dependent tumor and draining lymph node infiltration of DCs resulting in increased antigen-specific activation of CTLs (170).